- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02245009
Safety of External Electrocardioversion in Device Patients (SEED)
Safety of External Electrocardioversion in Device Patients - the SEED Registry
Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.
연구 개요
상세 설명
Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.
Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.
Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
-
Cologne, 독일, 50937
- 모병
- University Hospital Cologne
-
연락하다:
- Daniel Steven, Prof. Dr.
- 전화번호: 32396 +49221478
- 이메일: daniel.steven@uk-koeln.de
-
수석 연구원:
- Jakob Lüker, Dr.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Age ≥ 18 years
- Informed, written consent
- Atrial or ventricular arrhythmia with indication for CV
- Status post CRM implantation, including CRT-D
Exclusion Criteria:
- Age < 18 years
- Patients under guardianship or with mental disorders / disabilities
- lead implantation < 4 weeks prior to CV
- contraindications for eCV or transoesophageal echocardiographie (TOE)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
|
|
|
ICD patients
Patients with ICD, presenting for cardioversion.
|
|
|
CRT patients
Patients with CRT device, presenting for cardioversion.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite safety endpoint: Changes of lead and device parameters
기간: 2 weeks after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
2 weeks after CV
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy Endpoint
기간: within 15 minutes after CV
|
Assessed by device interrogation and 12-lead ECG: - restoration of normal sinus rhythm after CV |
within 15 minutes after CV
|
|
Late changes of lead parameters
기간: 2 weeks after CV
|
Any of the below, assessed by device interrogation:
|
2 weeks after CV
|
|
Inadvertent induction of ventricular fibrillation
기간: 10 seconds after CV
|
Assessed by 3 lead monitoring ECG
|
10 seconds after CV
|
|
Composite endpoint: Early lead changes
기간: within 15 minutes after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
within 15 minutes after CV
|
|
Loss of programming
기간: within 15 minutes after CV
|
assessed by device interrogation: - loss of programming of the device |
within 15 minutes after CV
|
|
Change of shock impedance
기간: within 15 minutes after CV
|
assessed by device interrogation: - rise in shock impedance by 50% |
within 15 minutes after CV
|
|
Change of charge time
기간: within 15 minutes after CV
|
assessed by device interrogation: - rise in charge time by 50% |
within 15 minutes after CV
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jakob Lüker, Dr., University Hospital Cologne
- 연구 책임자: Daniel Steven, Prof. Dr., University Hospital Cologne
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .